eprintid: 10109125
rev_number: 34
eprint_status: archive
userid: 608
dir: disk0/10/10/91/25
datestamp: 2020-09-02 10:37:34
lastmod: 2021-09-18 21:52:23
status_changed: 2021-02-02 11:56:22
type: article
metadata_visibility: show
creators_name: Blais, JE
creators_name: Akyea, RK
creators_name: Coetzee, A
creators_name: Chan, AHY
creators_name: Lau, WCY
creators_name: Man, KKC
creators_name: Harrison, J
creators_name: Chan, EW
creators_name: Beyene, KA
creators_name: Wong, ICK
creators_name: Weng, SF
title: Lipid levels and major adverse cardiovascular events in patients initiated on statins for primary prevention: an international population-based cohort study protocol
ispublished: pub
divisions: UCL
divisions: B02
divisions: C08
divisions: D10
divisions: G11
note: © 2020, The Authors. This article is Open Access: CC BY license (https://creativecommons.org/licenses/by/4.0/)
abstract: Background : Clinical guidelines recommend specific targets for low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C) for primary prevention of cardiovascular disease (CVD). Furthermore, individual variability in lipid response to statin therapy requires assessment of the association in diverse populations.

Aim: To assess whether lower concentrations of LDL-C and non-HDL-C are associated with a reduced risk of major adverse cardiovascular events (MACE) in primary prevention of CVD.

Design & setting: An international, new-user, cohort study will be undertaken. It will use data from three electronic health record databases from three global regions: Clinical Practice Research Datalink, UK; PREDICT-CVD, New Zealand (NZ); and the Clinical Data and Analysis Reporting System, Hong Kong (HK).

Method: New statin users without a history of atherosclerotic CVD, heart failure, or chronic kidney disease, with baseline and follow-up lipid levels will be eligible for inclusion. Patients will be classified according to LDL-C (<1.4, 1.4–1.7, 1.8–2.5, and ≥2.6 mmol/l) and non-HDL-C (<2.2, 2.2–2.5, 2.6–3.3, and ≥3.4 mmol/l) concentrations 24 months after initiating statin therapy. The primary outcome of interest is MACE, defined as the first occurrence of coronary heart disease, stroke, or cardiovascular death. Secondary outcomes include all-cause mortality and the individual components of MACE. Sensitivity analyses will be conducted using lipid levels at 3 and 12 months after starting statin therapy.

Conclusion: Results will inform clinicians about the benefits of achieving guideline recommended concentrations of LDL-C for primary prevention of CVD.
date: 2020
date_type: published
official_url: https://doi.org/10.3399/bjgpopen20X101127
oa_status: green
full_text_type: pub
language: eng
primo: open
primo_central: open_green
verified: verified_manual
elements_id: 1811067
doi: 10.3399/bjgpopen20X101127
lyricists_name: Chan, Amy Hai Yan
lyricists_name: Lau, Cheuk Yin
lyricists_name: Man, Keng
lyricists_name: Wong, Ian
lyricists_id: AHYCH99
lyricists_id: CYLAU57
lyricists_id: KCKMA73
lyricists_id: ICKWO00
actors_name: Lau, Cheuk Yin
actors_name: Allington-Smith, Dominic
actors_id: CYLAU57
actors_id: DAALL44
actors_role: owner
actors_role: impersonator
full_text_status: public
publication: BJGP Open
article_number: bjgpopen20X101127
citation:        Blais, JE;    Akyea, RK;    Coetzee, A;    Chan, AHY;    Lau, WCY;    Man, KKC;    Harrison, J;                 ... Weng, SF; + view all <#>        Blais, JE;  Akyea, RK;  Coetzee, A;  Chan, AHY;  Lau, WCY;  Man, KKC;  Harrison, J;  Chan, EW;  Beyene, KA;  Wong, ICK;  Weng, SF;   - view fewer <#>    (2020)    Lipid levels and major adverse cardiovascular events in patients initiated on statins for primary prevention: an international population-based cohort study protocol.                   BJGP Open      , Article bjgpopen20X101127.  10.3399/bjgpopen20X101127 <https://doi.org/10.3399/bjgpopen20X101127>.       Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/10109125/1/Lau_bjgpopen20X101127.full.pdf